Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. Wainwright
February 27, 2025 6:05 AM ESTH.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $400.00) while maintaining a Buy rating.
The analyst comments "We upgrade STLD to Peer Perform from Underperform, using updated steel price forecasts on Trump's pledged 25%... More
TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL), PT $390
February 26, 2025 3:55 PM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $390.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
The analyst comments "4Q/FY24 Rezdiffra revs were $103M/$180M, at the top of the preannouncement range. As of YE24, 11.8K+ pts were on Tx.... More
Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue
February 26, 2025 7:05 AM ESTMadrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.71), $1.77 better than the analyst estimate of ($4.48). Revenue for the quarter came in at $103.32 million versus the consensus estimate of $87.7 million.
For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.
... More